Mitochondria are organelles in eukaryotic cells that participate in a wide range of biological actions, such as energy metabolism, free oxygen radical generation, and cell apoptosis[@b1]. Usually thousands of mitochondria exist in each cell. Mitochondria possess separate copies of DNA (mtDNA), which are double-stranded, maternally inherited circular nucleotides with 16,569 base pairs encoding for 37 RNAs, including 13 mRNA, 22 transfer RNAs and two ribosomal RNAs. mtDNA content in cells typically ranges from 10^3^ to 10^4^ copies per cell and varies by cell type[@b2].

Due to the lack of protection from introns and histones, and less efficient DNA repair mechanisms, mtDNA is particularly susceptible to reactive oxidative species (ROS) and other sources of genotoxic damage, which may finally lead to sequence mutations or copy number alterations[@b3]. Changes in mtDNA copy number could alter the expression of mitochondrial genes and result in abnormal mitochondrial functions, such as energy production, signaling transduction, apoptosis and cell growth. Therefore, aberrant mtDNA content could potentially lead to alterations in oxidative phosphorylation, and enhance the production of ROS in aerobic metabolism, which can cause chromosomal aberrations such as base pair mutation and chromosome rearrangements, and finally facilitate the malignant transformation[@b4]. Contribution of mtDNA copy number alterations to nuclear genome damage has been confirmed by previous studies. Corral *et al*. found that introduction of mtDNA molecules to chemically-induced rat hepatomas and HT-1080 fibrosarcoma cell line caused an increased number of copies of COI, COII and COIII pseudogenes in the nuclear genome[@b5], while Delsite *et al*. demonstrated that a reduction in mitochondria in HeLa cells resulted in increased lipid peroxidation[@b6]. It has been shown that increased lipid peroxidation could induce damage directly to nuclear DNA[@b7].

Previous studies have reported quantitative changes in mtDNA content in patients' cancerous tissues compared with their normal counterparts, including an increase of mtDNA content in breast cancer and endometrial adenocarcinoma[@b8][@b9], and a decrease in colorectal cancer, cervical cancer, osteosarcoma and Ewing's sarcoma[@b10][@b11][@b12][@b13]. Moreover, the alteration of peripheral blood mtDNA content has also been found to be associated with tumor progression and patient prognosis. For example, lower peripheral blood leukocyte mtDNA copy number was correlated with aggressiveness and fast progression of prostate cancer[@b14]. Also, high mtDNA copy number in peripheral blood may predict a poor prognosis for hepatocellular carcinoma[@b15], glioma[@b16], colorectal cancer[@b17], and head and neck cancer[@b18]. Taken together, these results suggested that the alteration of mtDNA content might play complicated roles in tumorigenesis and progression in a cancer-specific manner.

As above, the involvement of mtDNA content changes in carcinogenesis remains controversial and ambiguous. Meanwhile, a single study might have been underpowered to detect the overall effects. Thus in this study we carried out a meta-analysis to summarize the existing evidence and to make a more precise evaluation about the relationship between mtDNA copy number and cancer risk among different populations.

Methods
=======

Literature search
-----------------

Relevant studies that estimated the association between mtDNA copy number and risk of cancers were identified from the databases of PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) up to March 1, 2016 by two investigators independently. The following key words were used for searching: "mitochondrial DNA", "risk" and "copy number". Other alternative spellings of these key words such as "content" and "susceptibility" were also used; only those publications in English were retained.

Inclusion and Exclusion criteria
--------------------------------

Studies were considered eligible for the current meta-analysis if they met the following criteria: (1) they assessed the relationship between mtDNA copy number (or mtDNA content) and risk (or susceptibility) of diverse cancer types; (2) used a cohort or case--control studies design; (3) had an appropriate description of mtDNA copy number in cases and controls; and (4) reported an odds ratio (OR) with a 95% confidence interval (CI) or other available data for calculating the OR (95% CI).

Exclusion criteria: (1) review articles and editorials; (2) case reports; (3) studies not focused on the mtDNA content and cancer risk; and (4) investigation of the functional role of mtDNA in carcinogenesis.

Data extraction
---------------

The following information from each eligible study was carefully extracted independently by two investigators: name of the first author, year of publication, country of origin, number of cases and controls, numbers of genotyped cases and controls, mitochondrial DNA haplotypes, subject population (categorized as East Asian, Indian, Western and Africa populations), source of controls (hospital-based \[HB\] and population-based \[PB\]), exposure to smoking, alcohol consumption, and body mass index (BMI).

Statistical analysis
--------------------

The strength of the association between mtDNA content and risk of diverse cancers was measured by calculating the odds ratio (OR) with a 95% confidence interval (95% CI), and two-tailed P \< 0.05 was considered as statistically significant. First, the overall association between mtDNA content and cancer risk was assessed by categorizing mtDNA content into high and low haplotypes based on cut-off points at the median, the 1^st^ tertile and the 2^nd^ quintile. Specifically, for those studies that categorized the mtDNA content into dichotomies or quartiles, the cut-off point was set at the median value in controls. For those studies categorizing mtDNA into tertiles, the 1^st^ tertile was treated as the low mtDNA content group, while the 2^nd^ and 3^rd^ tertiles were seen as the high mtDNA content group. For those studies that categorized mtDNA into quintiles, the 1^st^ and 2^nd^ quintiles were treated as the low content group, while the rest were designated as the high content group. The detailed information for the categorization is presented in [supplementary Table S1](#S1){ref-type="supplementary-material"}. Nested case-control studies and case-control studies were then combined to calculate the odds ratio in total and separately.

Further association analysis was performed by recruiting studies of quartiles to test if a dose-dependent relationship existed, under which condition the 1^st^ quartile was designated as the reference. Then we compared the odds ratio for the other quartiles with the reference to test whether the higher mtDNA contents correlated with cancer risk more obviously.

Heterogeneity among studies was further examined with the *I*^*2*^ statistic, which was interpreted as the proportion of total variation contributed by between-study variation. The Mantel--Haenszel method was used to calculate the OR for the pooled data in a fixed effects model if there was no evidence for significant heterogeneity. Otherwise a random effects model was selected to combine the data. Several subgroup meta-analyses were performed in an attempt to assess the association between the mtDNA content and cancer risk based on the population, age, gender, smoking status, alcohol drinking and BMI.

A sensitivity analysis was also performed to examine the reliability of our study by excluding individual studies orderly. Cumulative analysis was performed to explore the tendency of the changes in risk association by publication year. Evidence of publication bias was determined by visual inspection of the funnel plot and Egger's test. All statistical analyses were performed with STATA software (version 10.0; StataCorp, College Station, TX, USA). All P values are two-sided.

Results
=======

Characteristics of eligible studies
-----------------------------------

Finally, a total of 36 articles involving 11,847 cases and 15,438 controls were used in the current meta-analysis. By the sample sources according to original records, we classified these 36 articles into 39 independent study subgroups, among which there were twenty-five studies from Western populations, eleven from East Asia, two from India and one from Africa ([Table 1](#t1){ref-type="table"}). There were five studies with hospital-based controls and the others included population-based controls.

Among these 36 studies, five each focused on breast cancer, four each on renal clear cell carcinoma, three each on lung cancer, colorectal cancer, lymphoma and hepatic carcinoma /cirrhosis, two each on glioma, melanoma, oral and gastric cancer, and one each on nasopharyngeal cancer, endometrial cancer, prostate cancer, esophageal carcinoma, pancreatic carcinoma, soft tissue sarcoma and bladder cancer.

Most studies used ND1 and D-loop which were located on mtDNA as target regions to determine mtDNA copy number. Hemoglobin subunit beta (HBB), human globulin (HGB), 18 s RNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were the most widely used reference genes, and they are widely accepted single copy nuclear genes. All the information about the measurements applied in the studies can be obtained in [supplementary Table S1](#S1){ref-type="supplementary-material"}.

Association between mtDNA content and cancer risk in overall and stratified analyses
------------------------------------------------------------------------------------

When all studies were pooled for the overall meta-analysis by dichotomizing mtDNA copy number into high and low content groups, there was no significant association between mtDNA content and overall cancer risk (OR = 1.044, 95% CI 0.866--1.260, P = 0.651), and there was high heterogeneity (*I*^*2*^ = 92.4%), which may be explained by different cancer types and populations ([Fig. 1](#f1){ref-type="fig"}).

Results of the subgroup analyses are presented in [Table 2](#t2){ref-type="table"}. Stratification analysis by cancer types identified increased cancer risk associated with high mtDNA content in the subgroups of breast cancer (OR = 1.721, 95% CI = 1.130--2.622, p = 0.011) and lymphoma (OR = 1.645, 95% CI = 1.117--2.421, p = 0.012 respectively), with high and moderate heterogeneity, respectively (*I*^*2*^ = 92.6% and 51.6%). Marginal increased risk associated with high mtDNA content was found in melanoma and glioma, with an odds ratio of 1.555 (95% CI = 0.598--4.045, p = 0.365, *I*^*2*^ = 93.6%) and 2.510 (95% CI = 0.709--8.887, p = 0.154, *I*^*2*^ = 97.2%), respectively. In contrast, mtDNA content was negatively significantly correlated with hepatic malignancy (OR = 0.622, 95% CI = 0.486--0.798, p = 0.000). We further categorized the studies by organ systems, such as digestive, respiratory, gynecological and urinary carcinoma. However, no significant association was identified in any group.

Further subgroup analyses were performed by stratifying studies according to population, age, and gender, as well as life styles such as smoking status, alcohol consumption and body mass index ([Table 2](#t2){ref-type="table"}). The results revealed that high mtDNA content may predict increased carcinogenesis risk in people with drinking addiction (OR = 1.261, 95% CI = 1.076--1.479, p = 0.004). A total of five studies that provided drinking-related data were included for stratified analysis, and it is notable that four of these studies came from digestive cancers, indicating that high mtDNA content accompanied by drinking addiction may contribute to elevated digestive cancer risk.

According to the study design, we classified the studies into nested case-control and case-control studies ([supplementary Table S1](#S1){ref-type="supplementary-material"}), and we performed association analysis based on the study design as well ([Table 3](#t3){ref-type="table"}). The results from the nested case-control and case-control study did not differ significantly from the results above, which demonstrated the stability and reliability of our analysis. It was surprising to find that mtDNA content was negatively significantly correlated with renal cancer risk in the case-control studies, which was obscured in the stratified analysis in the previous section.

Cancer risk increased as mtDNA content elevated by quartile analyses
--------------------------------------------------------------------

To investigate the possible dose-dependent relationship between mtDNA content and cancer risk, we enrolled the studies that categorized mtDNA copy number into quartiles for further analysis and assigned the 1^st^ quartile as the reference. A total of 20 studies were included in the dose-dependent relationship analyses. No significant difference was found in the risk among carriers of the 2^nd^, 3^rd^ and 4^th^ quartiles in the overall analysis. However, stratified analysis by cancer types found that carriers of higher mtDNA content exhibited gradually increasing risk for breast cancer and melanoma ([Table 4](#t4){ref-type="table"}), which is consistent with the findings in the dichotomous meta-analysis, further supporting the idea that high mtDNA predisposes increased risk in breast cancer and melanoma. After grouping studies by population, the association of mtDNA content in 4^th^ quartiles with cancer risk was more obvious in western populations than in Asians (OR = 1.122, p = 0.016 versus OR = 0.981, p = 0.896). There were no obvious differences in cancer risk among males and females or among frequent and infrequent smokers.

Cumulative analysis
-------------------

The findings from the cumulative meta-analysis showed that the positive association was more obvious in early studies but decreased as the data increased by publication year, and the association strength remained stable in the 95% confidence intervals with increasing sample sizes in recent years ([Fig. 2](#f2){ref-type="fig"}), which further demonstrated the complicated roles of mtDNA content in diverse carcinogenesis.

Sensitivity analyses
--------------------

A sensitivity analysis was conducted to assess the influence of each study by sequential omission of each eligible study both in the overall meta-analysis and stratified analysis. The results showed that the significance of the OR was not affected by any single study ([Fig. 3](#f3){ref-type="fig"}), indicating the reliability of our study.

Evaluation of publication bias
------------------------------

Both Begg's funnel plot and Egger's test were performed to assess the publication bias. The shape of the funnel plots did not reveal any evidence of obvious asymmetry for any genetic model in the overall meta-analysis ([Fig. 4](#f4){ref-type="fig"}). Next, Egger's test was used to provide statistical evidence for the funnel plot symmetry, and the results still did not suggest any obvious evidence of publication bias (P = 0.868). Thus, there was no obvious risk of publication bias in this meta-analysis.

Discussion
==========

Mitochondria are energy factories that produce adenosine triphosphate (ATP) through oxidative phosphorylation. Both increased and decreased mtDNA copy number in blood have been previously reported to be associated with cancer risk in a cancer-specific manner. For example, it has been reported that increased mtDNA copy number contributes to high risk for breast cancer and lymphoma, while decreased mtDNA content was relevant to renal and colorectal cancers. The opposite effects brought out by altered mtDNA content may represent diverse biological roles that mtDNA plays in malignancies.

Biologically, lowered mtDNA copy number can cause deficiency in oxidative phosphorylation and enhanced production of toxic metabolites in aerobic metabolism and glycolysis, resulting in the disruption of cellular functions. Also, it has been demonstrated that mtDNA reduction promotes cancer cells to become more resistant to apoptosis, and leads to epithelial-mesenchymal transition (EMT)[@b19][@b20], an important process by which epithelial cells lose their cell polarity and cell-cell adhesion and acquire mesenchymal, fibroblast-like characteristics, accompanied by increased cell migratory and invasive properties, thus endowing the incipient cancer cell with invasive and metastatic properties[@b21]. On the other hand, high mtDNA content can be an indicative marker of oxidative stress, which is associated with environmental exposure to pollutants, tobacco, smoke, drugs, xenobiotics, or radiation. High mtDNA content is also an important marker of an impaired aerobic mechanism that is thought to be involved in the molecular mechanisms of carcinogenesis[@b22]. These observations together suggest a complicated role for the changes in mtDNA copy number on the modulation of cancer risk. In the present study, we performed this meta-analysis to achieve a more conclusive result.

Our analysis included 36 studies that focused on diverse cancer types from different origins around the world[@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58]. To reduce the uncertainty induced by confusing factors in the meta-analysis, we evaluated the association between mtDNA content with cancer risk in an overall analysis, as well as stratified analyses by cancer types, genders, ages, ethnicity and life styles.

Finally, we did not find an obvious association between mtDNA content and cancer risk in the overall analysis, which should be the result of the heterogeneity among different cancer types. Thus subgroup analyses were performed to further detect the association strength. Stratified analysis by cancer types provided evidence on the relationship between high mtDNA content and increased breast cancer and lymphoma risk. Dose-dependent effects were also found for melanoma risk. The biological contribution of increased mtDNA content in the peripheral blood to carcinogenesis remains obscured. Previous studies found a correlation between mtDNA content and markers of oxidative stress, such as thiobarbituric acid reactive substances and 8-hydroxyguanosine[@b59]. Moreover, lower levels of antioxidants were also detected in blood with an increased mtDNA copy number. Due to lack of sufficient protective mechanisms, mtDNA mutations may occur during the process of oxidative stress, and certain mtDNA mutations may lead to the generation of increased superoxide and nitric oxide, resulting in aberrant mitochondrial biogenesis[@b60], which has been associated with deficient or defective apoptosis, and confers a replicative advantage to the cells[@b59]. Therefore it is plausible that high mtDNA content in peripheral blood leukocytes may be indicative of increased oxidative stress, impaired aerobic metabolism, and ROS-mediated DNA damage. mtDNA copy number may increase to compensate for mtDNA damage and mitochondrial dysfunction[@b3]. Thus it is more likely that the increased mtDNA content is a significant marker of carcinogenesis associated oxidative stress, but not a cause of cancer development.

Stratified analysis also found a significant negative association between mtDNA content and susceptibility of hepatic carcinoma, suggesting the complexity of the involvement of mtDNA changes in carcinogenesis in different populations, which should not be explained by any single mechanism. It has been demonstrated that mtDNA decrease alters mitochondrial gene expression, resulting in deficiency in oxidative phosphorylation, and causes a disturbance of cellular functions. Warburg proposed that damage to the respiratory chain was a critical event in carcinogenesis[@b61], which demonstrates that cancer cells enhanced the generation of adenosine triphosphate by glycolysis[@b62], resulting in a stronger tolerance to hypoxia and reducing the dependence of mitochondrial oxidative phosphorylation, thus conferring tumor cells the advantages of growth. Enhanced glycolysis also leads to excessive production of lactate and prosurvival proteins, which may initiate and promote cancer development. MtDNA reduction was also found to increase cancer cells' resistance to apoptosis and lead to epithelial-mesenchymal transition, which are both common in tumor formation and metastatic progression. Some previous studies have partially explained the mechanism by which mtDNA reduction acts on apoptosis resistance and epithelial-mesenchymal transition. Biswas *et al*. reported that decreased mtDNA content could activate NFkappaB/Rel factors[@b63]. Activation of nuclear factor-kappa B signaling plays a critical role in apoptosis resistance and is clearly linked to various cancer malignant transformation[@b64]. In addition, activation of the AKT pathway by an mtDNA deficiency could also inhibit cell apoptosis[@b65][@b66]. As for the contribution to EMT, mtDNA loss may activate PI3K/Akt2, and Raf/MAPK pathways, which may finally lead to EMT and cancer metastasis[@b67][@b68].

Stratified analysis by life styles, such as smoking, drinking and BMI status, suggested alcohol users with high mtDNA content may be more susceptible to cancer development, indicating an intrinsic relationship between mtDNA and alcohol degradation. Surprisingly, we did not find any association between altered mtDNA and smoking-related malignancies, although it has been widely accepted that smoking is an important stimulator of diverse cancers. Previous evidence has shown that the metabolites of cigarettes should be oxidative phosphorylated by mitochondria, so we proposed that abnormal mtDNA content may predict altered cancer risk in the smoking population. However, we did not obtain the suspected results, indicating that tumor-genesis of smoking related cancers involves much more cellular abnormality than mtDNA changes.

In summary, our study provides evidence that increased mtDNA content is statistically significantly associated with risk of lymphoma, breast cancer and melanoma, but is negatively associated with hepatic carcinoma. The mechanism for the tumor specific associations between mtDNA content and cancer risk remain to be illustrated, although they are likely to be regulated by a wide range of genetic, molecular, and cellular determinants. For instance, elevated mtDNA content has been significantly associated with altered oxidative stress, aging, immune response activation, and response to environmental exposure. Future studies are warranted to evaluate oxidative stress related factors that influence mtDNA copy number and to provide novel insights into the biological mechanisms of mtDNA copy number variation on the development of various cancers, especially on the opposite effects of increased and decreased mtDNA content in carcinogenesis. Furthermore, many more subjects are needed to confirm the association identified by our meta-analysis in different populations.
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###### Study and host characteristics included in this meta-analysis.

  Author         Year          Cancer type          Sample source        Country        Ethnicity   Sample size Ca/Co   Gender    Age, year old Ca/Co   BMI, kg/m^2^ Ca/Co Ca/Co   Smoking status   Drinking status                       
  ------------- ------ --------------------------- --------------- ------------------- ----------- ------------------- --------- --------------------- -------------------------- ---------------- ----------------- ---------- --------- ----------
  Lan            2008           lymphoma             Population          Finland        Caucasian        104/104          Un              Un                     58/57               25.5/25.4            Un             Un        Un         Un
  Shen           2010         Breast cancer          Population            USA          Caucasian        103/103          Un            103/103                  58/56               27.8/26.4           52/51           Un       75/78       Un
  Xing           2009     Renal cell carcinoma       Population            USA          Caucasian        260/281        172/175         88/106                     Un                    Un             134/126       125/155      Un         Un
  Bonner         2009          Lung cancer           Population           China           Asian          113/107         73/68           40/39                 54.9/54.5                 Un               Un             Un        Un         Un
  Hosgood        2010          Lung cancer           Population          Finland        Caucasian        227/227        227/227           0/0                  58.7/58.4             25.6/26.3          227/227         0/0        Un         Un
  Liao           2011        Gastric cancer          Population           China           Asian          162/299          0/0           162/299                61.0/61.0                 Un               Un             Un        Un         Un
  Lynch          2011          pancreatic            Population          Finland        Caucasian        203/656        203/656           0/0                  58.0/58.0             26.2/25.7          203/656         0/0        Un         Un
  Qu             2011          Colorectal            Population           China           Asian          320/320        169/151         169/151                58.4/58.2             23.8/23.6          126/105       194/215     42/35    278/285
  Zhao           2011   Hepatocellular carcinoma     Population           China           Asian          274/384        236/218          38/40                 50.1/48.7                 Un             154/132       120/126     98/42    176/216
  Purdue         2012     Renal cell carcinoma       Population            USA          Caucasian        445/379        256/247         189/132                    Un                    Un             293/231       152/148      Un         Un
                                                     Population                          African         158/224        109/110         49/114                     Un                    Un             112/154        46/70       Un         Un
  Thyagarajan    2012          Colorectal            Population     Singapore Chinese     Asian          422/874        250/380         172/494                66.1/57.6             23.0/22.8          181/228       241/646      Un         Un
  Mondal         2012             Oral                Hospital            India           Asian          124/140         98/26          101/39                   58/56                   Un              89/75         35/65       Un         Un
  Thyagarajan    2013            Breast              Population     Singapore Chinese     Asian          183/529          0/0           183/529                61.1/61.1                 Un               Un             Un        Un         Un
  Xie            2013      Soft tissue sarcoma       Population            USA            Mixed          325/330        174/180         151/150               58.24/58.50                Un             122/117       174/212      Un         Un
  Xu             2013   Esophageal adenocarcinoma    Population            USA          Caucasian        218/218        173/173          45/45                62.05/60.94                Un             150/122        68/96       Un         Un
  Ghosh          2014   Nasopharyngeal carcinoma      Hospital            India           Asian          64/100          49/79           15/21                     Un                    Un              45/26         19/74       Un         Un
  Hoffman        2014     Renal cell carcinoma       Population            USA          Caucasian        230/468        164/331         66/137                     Un                    Un             212/256        92/138      Un         Un
  Hosnijeh       2014           lymphoma             Population         European        Caucasian        469/469        231/231         238/238                56.6/56.6             26.9/26.6          272/264       197/205      Un         Un
  Huang          2014       Colorectal cancer        Population           China           Asian         444/1423          0/0          444/1423                58.6/55.2             24.6/24.4           11/46        433/1377    14/39    430/1384
  Jiang          2014         Breast cancer          Population           China           Asian          506/520          0/0           506/520                    Un                    Un               Un             Un        Un         Un
  Kim ATBC       2014          Lung cancer           Population          Finland        Caucasian        227/227        227/227                               56.67/58.41           25.59/26.35         227/227          Un        Un         Un
  Kim PLCO                                           Population            USA            Mixed          426/436        259/267         167/169               64.07/63.67           26.84/27.43         380/238          Un        Un         Un
  Kim SWHS                                           Population           China           Asian          221/222          0/0           221/222                59.2/59.2            24.58/25.01          17/11           Un        Un         Un
  Sun            2014            gastric             Population            USA          Caucasian        132/125         74/65           58/60                 58.2/55.5                 Un              55/82         77/43       Un         Un
  Zhang          2014            glioma              Population           China           Asian          414/414        241/241         173/173                    Un                    Un              96/85        318/329      Un         Un
  Zhou           2014        Prostate cancer         Population           China           Asian          193/194        193/194           0/0                  70.3/70.1             24.1/23.2          100/98         93/96       Un         Un
  Hyland         2014           Melanoma             Population            USA            Mixed          136/302        130/63          172/73                     Un                    Un               Un             Un        Un         Un
  Kim ATBC       2015           lymphoma             Population          Finland        Caucasian        142/142        142/142           Un                       Un                    Un             142/142         0/0        Un         Un
  Kim PLCO       2015           lymphoma             Population            USA            Mixed          292/301        178/185         114/116                    Un                    Un             135/155       157/146      Un         Un
  Lemnrau        2015         Breast Cancer          Population            UK           Caucasian       1053/1053         Un              Un                       Un                    Un             428/410       679/687    981/936   125/160
  Melkonian      2015     Renal cell carcinoma       Population            USA          Caucasian        608/629        400/418         208/211               58.46/58.57                Un             297/287       311/342      Un         Un
  Shen           2015            breast              Population            USA          Caucasian       1000/1000         Un           1000/1000                 58/56               27.8/26.4          315/288       685/712    720/750   280/250
  Shen           2015           melanoma             Population            USA            Mixed          500/500        238/262         238/262                    Un                    Un               Un             Un        Un         Un
  He             2014    Oralpremalignant lesion     Population            USA            Mixed          143/357        87/215          56/142                 57.3/58.5                 Un             83/175         60/182    85/108     53/249
  Sun            2015          Endometrial            Hospital             USA          Caucasian        139/139          Un              Un                  62.24/61.76                Un              31/48         108/91      Un         Un
  Wang           2015        Liver Cirrhosis          Hospital             USA          Caucasian        136/136        112/105          24/31                54.17/54.03                Un              55/54         81/82      68/60     68/76
  Williams       2015        Bladder cancer           Hospital             USA          Caucasian        926/926        738/738         188/188                    Un                    Un             678/521       248/405      Un         Un
  Hashad         2015   Liver Carcinoma/Cirrhosis    Population           Egypt          African          90/45          52/30           38/15                  50.88/50                 Un               Un             Un        Un         Un
  Shen           2016            Glioma              Population            USA          Caucasian        395/425        242/221         149/204                  49/52               28.2/27.6          175/216       198/204      Un         Un

Un: Unknown data.

###### Overall and subgroup analyses of mtDNA copy number with cancer risk by dichotomizing mtDNA copy number into high and low groups.

  Subgroups                         Research counts (n)   Test of association   95% CI        P                 Heterogeneity             *I*^2^   *Tau-squared*          
  -------------------------------- --------------------- --------------------- -------- ------------- ---------------------------------- -------- --------------- ------- --------
  **Overall**                               39                  Random          1.044    0.866-1.260                0.651                 499.08       0.000       92.4%   0.3139
  Cancer types                                                                                                                                                            
   Lymphoma                                  4                  Random          1.645    1.117-2.421   0.012[a](#t2-fn1){ref-type="fn"}    6.20        0.102       51.6%   0.0769
   Breast cancer                             5                  Random          1.721    1.130-2.622   0.011[a](#t2-fn1){ref-type="fn"}   54.16        0.000       92.6%   0.2015
   Lung cancer                               5                  Random          0.982    0.788-1.223                0.871                  7.84        0.097       49.0%   0.2015
   Colorectal cancer                         3                  Random          1.168    0.638-2.139                0.641                 34.38        0.000       94.2%   0.2681
   Renal carcinoma                           4                  Random          0.856    0.598-1.226                0.397                 19.71        0.000       84.8%   0.1126
   Melanoma                                  2                  Random          1.555    0.598-4.045                0.365                 15.73        0.000       93.6%   0.4456
   Glioma                                    2                  Random          2.510    0.709-8.887                0.154                 35.96        0.000       97.2%   0.8091
   Gastric                                   2                  Random          0.412    0.054-3.134                0.392                 25.76        0.000       96.1%   2.0587
   Hepatic                                   3                   Fixed          0.622    0.486-0.798   0.000[a](#t2-fn1){ref-type="fn"}    0.53        0.767       0.0%       
   Oral                                      2                  Random          0.946    0.295-3.029                0.925                 12.43        0.000       92.0%   0.6489
  Organ systems                                                                                                                                                           
   Digestive system                         12                  Random          0.861    0.632-1.173                0.344                 95.74        0.000       88.5%   0.2521
   Urogenital system                         6                  Random          0.876    0.635-1.209                0.420                 43.03        0.000       88.4%   0.1398
   Respiratory system                        6                  Random          0.928    0.730-1.179                0.539                 11.74        0.039       57.4%   0.0488
   Gynecologica system                       6                  Random          1.253    0.744-2.109                0.396                 106.55       0.000       95.3%   0.3847
  Population                                                                                                                                                              
   Western                                  25                  Random          0.951    0.719-1.259                0.728                 456.55       0.000       94.7%   0.4628
   East Asian                               11                  Random          1.296    0.901-1.866                0.162                 147.15       0.000       93.2%   0.3481
   India                                     2                   Fixed          0.508    0.335-0.771                0.001                  0.01        0.938       0.0%       
   Africa                                    1                                  0.799                                                                                         
  Age[b](#t2-fn2){ref-type="fn"}                                                                                                                                          
   Elder                                    10                  Random          1.104    0.655-1.860                0.710                 111.22       0.000       91.9%   0.6352
   Younger                                  10                  Random          1.079    0.670-1.738                0.754                 95.11        0.000       90.5%   0.5213
  Gender                                                                                                                                                                  
   Male                                     16                  Random          1.036    0.755-1.420                0.828                 155.98       0.000       90.4%   0.3578
   Female                                   22                  Random          1.109    0.866-1.420                0.414                 191.26       0.000       89.0%   0.2788
  Life styles                                                                                                                                                             
   Smoking status                                                                                                                                                         
    Ever/Frequent                           21                  Random          0.984    0.765-1.267                0.902                 106.17       0.000       81.2%   0.2465
    Never/Occasionally                      18                  Random          1.047    0.736-1.491                0.798                 165.82       0.000       89.7%   0.4972
   Drinking Status                                                                                                                                                        
    Ever/Frequent                            5                   Fixed          1.261    1.076-1.479   0.004[a](#t2-fn1){ref-type="fn"}    4.53        0.340       11.6%      
    Never/Occasionally                       5                  Random          1.179    0.971-1.432                0.096                 42.69        0.000       90.6%   0.5403
   BMI                                                                                                                                                                    
    High^c^                                  4                  Random          1.103    0.413-2.942                0.845                 36.84        0.000       91.9%   0.9038
    Low^c^                                   4                  Random          1.077    0.550-2.109                0.828                 15.12        0.002       80.2%   0.3609

^a^p \< 0.05;

^b^Age was classified as elder and younger according to publication records; ^c^Relative value which means relatively high and relatively low BMI.

###### Comparison of cancer risk association between nested case-control and case-control studies.

  Subgroups                                      Research counts (n)   Test of association   95% CI        P                 Heterogeneity             *I*[2](#t3-fn2){ref-type="fn"}   *Tau-squared*          
  --------------------------------------------- --------------------- --------------------- -------- ------------- ---------------------------------- -------------------------------- --------------- ------- --------
  Overall                                                                                                                                                                                                      
   *Nested case-control*                                 16                  Random          1.133    0.957-1.342                0.651                             62.08                    0.000       75.8%   0.0816
   Case-control                                          23                  Random          0.958    0.708-1.297                0.783                             436.96                   0.000       95.0%   0.5011
  Cancer types                                                                                                                                                                                                 
   *Lymphoma*[a](#t3-fn1){ref-type="fn"}                  4                  Random          1.645    1.117-2.421   0.012[c](#t3-fn3){ref-type="fn"}                6.20                    0.102       51.6%   0.0769
   *Breast cancer*                                        2                   Fixed          1.360    1.165-1.587   0.000[c](#t3-fn3){ref-type="fn"}                1.77                    0.183       43.6%      
   *Breast cancer*[b](#t3-fn2){ref-type="fn"}             3                  Random          2.001    0.897-4.468                0.090                             46.98                    0.000       95.7%   0.4645
   *Lung cancer*                                          4                  Random          0.888    0.752-1.049                0.163                              2.29                    0.514       0.0%    0.2015
   *Lung cancer*                                          1                                  0.669                                                                                                                 
   *Colorectal cancer*                                    2                  Random          0.891    0.760-1.045                0.156                             14.68                    0.000       93.2%      
   *Colorectal cancer*                                    1                                  1.991                                                                                                                 
   *Renal carcinoma*                                      1                                  1.584                                                                                                                 
   *Renal carcinoma*                                      3                   Fixed          0.711    0.611-0.827   0.000[c](#t3-fn3){ref-type="fn"}                0.15                    0.926       0.0%       
   *Melanoma*                                             2                  Random          1.555    0.598-4.045                0.365                             15.73                    0.000       93.6%   0.4456
   *Glioma*                                               2                  Random          2.510    0.709-8.887                0.154                             35.96                    0.000       97.2%   0.8091
   *Gastric*                                              2                  Random          0.412    0.054-3.134                0.392                             25.76                    0.000       96.1%   2.0587
   *Hepatic*                                              1                                  0.600                                                                                                                 
   *Hepatic*                                              2                   Fixed          0.630    0.472-0.842   0.002[c](#t3-fn3){ref-type="fn"}                0.50                    0.479       0.0%       
   *Oral*                                                 2                  Random          0.946    0.295-3.029                0.925                             12.43                    0.000       92.0%   0.6489
  Organ systems                                                                                                                                                                                                
   *Digestive system*                                     5                  Random          0.920    0.673-1.258                0.602                             20.22                    0.204       80.2%   0.0975
   *Digestive system*                                     7                  Random          0.711    0.399-1.266                0.247                             75.74                    0.000       92.1%   0.5452
   *Urogenital system*                                    1                                  1.584                                                                                                                 
   *Urogenital system*                                    5                  Random          0.808    0.637-1.025                0.079                             16.11                    0.003       75.2%   0.0533
   *Respiratory system*                                   4                  Random          0.888    0.752-1.049                0.163                              2.29                    0.514       0.0%    0.2015
   *Respiratory system*                                   2                  Random          0.942    0.279-3.181                0.924                              7.97                    0.005       87.4%   0.6742
   *Gynecologica system*                                  2                   Fixed          1.360    1.165-1.587   0.000[a](#t3-fn1){ref-type="fn"}                1.77                    0.183       43.6%      
   *Gynecologica system*                                  4                  Random          1.143    0.443-2.949                0.782                             103.65                   0.000       97.1%   0.8848

^a^The bold inclined letters indicate the nested case-control study.

^b^The thin inclined letters indicate the case-control study.

^c^p \< 0.05.

###### Overall and subgroup analyses of mtDNA copy number with cancer risk in quartiles.

  Study groups            Studies (n)   4^th^ versus 1^st^ quartile        p         *I*^*2*^   3^rd^ versus 1^st^ quartile     p      *I*^*2*^     2^nd^ versus 1^st^ quartile     p     *I*^*2*^                         
  ---------------------- ------------- ----------------------------- -------------- ---------- ----------------------------- ------- ------------- ----------------------------- ------- ---------- -------------- ------- -------
  Overall                     21                   1.025              0.765-1.373     0.870                90.4%              0.923   0.743-1.146              0.466              81.9%    0.925     0.777-1.101    0.382   71.9%
  Cancer types                                                                                                                                                                                                             
   Breast cancer               2                   1.906              0.974-3.729     0.060                92.9%              1.573   0.973-2.542              0.065              85.8%    1.250     0.811-1.927    0.312   81.8%
   Lung cancer                 4                   1.068              0.783-1.456     0.677                40.5%              0.816   0.640-0.040              0.100              0.0%     1.111     0.880-1.401    0.376   0.0%
   Renal cancer                2                   0.594              0.456- 0.775    0.000                97.4%              0.572   0.437-0.749              0.000              96.2%    0.511     0.387-0.674    0.000   93.0%
   Melanoma                    2                   1.792              1.313-2.445     0.000                87.9%              1.696   1.240-2.320              0.001              49.9%    1.544     1.124-2.119    0.007   10.2%
  Organ systems                                                                                                                                                                                                            
   Digestive cancers           5                   0.997              0.806-1.233     0.978                78.7%              0.673   0.537-0.845              0.001              65.7%    0.622     0.495-0.780    0.000   48.3%
   Urogenital cancers          4                   0.788              0.663-0.938     0.007                92.0%              0.860   0.724-1.021              0.085              84.2%    0.864     0.726-1.026    0.096   57.8%
  Population                                                                                                                                                                                                               
   Western                    14                   1.122              1.022-1.233     0.016                90.8%              0.916   0.831-1.008              0.073              84.1%    0.881     0.799-0.971    0.010   74.7%
   East Asian                  5                   0.981              0.739-1.303     0.896                80.8%              0.962   0.727-1.272              0.784              73.0%    0.962     0.727-1.272    0.784   73.0%
  Gender                                                                                                                                                                                                                   
   Male                        6                   0.762              0.622-0.934     0.009                90.7%              0.662   0.535-0.819              0.000              63.7%    0.768     0.625-0.944    0.012   48.0%
   Female                      6                   0.720              0.563-0.920     0.009                80.0%              0.750   0.588-0.957              0.020              55.2%    0.733     0.572-0.939    0.014   70.5%
  Life styles                                                                                                                                                                                                              
   Smoking staus                                                                                                                                                                                                           
    Ever/Frequent              5                   1.121              1.005-1.250     0.040                43.5%              1.031   0.918-1.158              0.603              57.0%    1.036     0.919-1.167    0.563   0.0%
    Never/occasionally         5                   1.117              1.001-1.247     0.048                0.0%               1.054   0.939-1.182              0.372              0.0%     1.018     0.906- 1.144   0.761   0.0%
   Drinking status                                                                                                                                                                                                         
    Ever/Frequent              1                   1.149              1.024-1.289     0.018                                   1.075   0.953-1.212              0.242                       0.998     0.875-1.138    0.974      
    Never/occasionally         1                   1.137              0.790-1.635     0.489                                   1.160   0.862-1.562              0.328                       1.040     0.749-1.444    0.814      
   BMI                                                                                                                                                                                                                     
    High                       1                   1.398              1.131-1.728     0.002                                   1.227   0.976-1.543              0.080                       1.053     0.796-1.391    0.719      
    Low                        1                   0.950              0.609-1.481     0.820                                   1.058   0.700-1.599              0.790                       1.023     0.665-1.574    0.917      

[^1]: These authors contributed equally to this work.
